Tech Company Financing Transactions
Asylia Therapeutics Funding Round
Asylia Therapeutics, operating out of Houston, raised $14.5 million in funding from Sporos Bioventures and private investors.
Transaction Overview
Company Name
Announced On
5/27/2021
Transaction Type
Venture Equity
Amount
$14,500,000
Round
Series A
Investors
Sporos Bioventures (Lead Investor)
Proceeds Purpose
The funds will be deployed to bring Asylia's multiple assets to first-in-human clinical trials for oncology and at the same time potentially generate proof-of-concept signals in auto-immune diseases such as lupus.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd. J
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Karthik Radhakrishnan
Chief Scientific Officer
Jeno Gyuris
Co-Founder
Richard Jones
Founder
Ronald DePinho
Founder
Robert Orlowski
Browse more venture capital transactions:
Prev: 5/27/2021: TerraClear venture capital transaction
Next: 5/27/2021: Hello Heart venture capital transaction
Share this article
About Our VC Transactions Data
We document all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs